EFTA00967207.pdf

From: "Jeffrey E." <[email protected]> To: Masha Drokova < >, Steven Sinofsky Subject: Re: Date: Wed, 01 Nov 2017 16:31:14 +0000 steve can you give some guidance On Wed, Nov 1, 2017 at 12:20 PM, Masha Drokova < > wrote: I'm looking to invest at the company doing AI-based glucose monitoring system for people with diabetes. We made tech evaluation, talked to a few experts and more a question about the market and regulations. Likely no, because it's complex area, but still thinking of them. May be someone in your network who knows this area and can advise on this kind of tech? Center Health Deck: Our memo: Center Health is building an AI-based glucose monitoring system for the 1 in 11 Americans who suffer from diabetes, based on machine learning and their personalized Al, Aria. Users subscribe to their disposable test strips, a $14B/yr US market, which are delivered monthly, as Aria learns about their diabetes and prompts behavioral changes to lower blood sugar. The system is an order of magnitude cheaper than existing technologies, premised on leveraging data to help users see what daily elements are affecting their blood sugar, and predicting dangerous highs and lows before they happen. Pins — Existing glucometers from big companies are very old-fashioned and outdated, those companies make their revenue from overpriced strips — Direct competitors, such as iHealth and Dario have negative customer reviews and minor — Uses FDA-approved circuits to get the approval in an automated manner Cons — Enormous pressure both from the industry players and companies such as Apple and Google that try to develop non-invasive glucose monitoring that will wipe out test strip products — Hardware startup without a product to sell yet, finalizing the development — Young team please note The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of JEE Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by EFTA00967207 return e-mail or by e-mail to [email protected], and destroy this communication and all copies thereof, including all attachments. copyright -all rights reserved EFTA00967208